TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Nasdaq Scores New Record for Third Day in a Row; Dow and S&P 500 Decline
FUTURES

Nasdaq Hits 6,000 in Busy Day of Milestones For Wall Street

  • By Keris Alison Lahiff
  • Apr 25, 2017 4:09 PM EDT
PRESS RELEASES

Forward Pharma Announces New Date For The EP2801355 Appeal Hearing Due To COVID-19

  • By GlobeNewswire
  • May 12, 2020 5:00 PM EDT
Nasdaq Scores New Record for Third Day in a Row; Dow and S&P 500 Decline
FUTURES

Nasdaq Hits 6,000 in Busy Day of Milestones For Wall Street

  • By Keris Alison Lahiff
  • Apr 25, 2017 4:09 PM EDT
Wall Street Backs Off of Records After London Terror Attack, Crude Oil Drop
FUTURES

Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017

  • By Keris Alison Lahiff
  • Apr 25, 2017 2:28 PM EDT
Wall Street Backs Off of Records After London Terror Attack, Crude Oil Drop
FUTURES

Caterpillar Hauls Dow Sharply Higher, Nasdaq Tops 6,000 for First Time

  • By Keris Alison Lahiff
  • Apr 25, 2017 10:42 AM EDT
Wall Street Backs Off of Records After London Terror Attack, Crude Oil Drop
FUTURES

Stock Futures See More Gains on a Stream of Positive Earnings

  • By Keris Alison Lahiff
  • Apr 25, 2017 8:28 AM EDT
Biogen Resolves Multiple Sclerosis Drug Dispute
VIDEO

Biogen Resolves Multiple Sclerosis Drug Dispute

  • By Anders Keitz
  • Jan 17, 2017 5:09 PM EST
Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects
HEALTH

Forward Pharma shares jump on Biogen license agreement

  • By Armie Margaret Lee
  • Jan 17, 2017 12:00 PM EST
Citi Calls Biogen The Biotech 'Stock To Watch' In 2016 With $90 Upside Possible
STOCKS

Biogen is a takeover target but don't ignore the risks

  • By Adam Feuerstein
  • Aug 3, 2016 7:01 AM EDT
PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe
STOCKS

Diarrhea Dings Xenoport Psoriasis Drug Study Results

  • By Adam Feuerstein
  • Sep 15, 2015 9:59 AM EDT
Germany's Merck Lifts Full-Year Guidance After Sigma-Aldrich Boosts Sales
INVESTING

4 Stocks Breaking Out on Unusual Volume: Forward Pharma and More

  • By Roberto Pedone
  • Mar 16, 2015 12:36 PM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.